BioNxt Solutions' pharmaceutical revolution: New ways of administering blockbuster drugs

A journey through a productive fall

It began on September 2 with a seemingly technical but crucial announcement. BioNxt Solutions had the high-purity active ingredient semaglutide in hand. This marked the starting signal for practical work on the oral dissolvable film, the potential needle-free alternative to blockbusters such as Ozempic®. "Now that we have the active ingredient available on site, we can put theory into practice," commented CEO Hugh Rogers on this step. The development team in Munich immediately began optimizing the formulation.

Three days later, the next strategic step followed. The uplisting to the OTCQB market in the US was completed. This change opened up the stock to a broader US investor base and highlighted the Company's claim to position itself as a serious development partner. Rogers emphasized the "positive upward momentum of the Company" and referred to three proprietary programs in Europe.

September 15 then brought the first major technical confirmation. The proof-of-concept studies for the semaglutide dissolvable film were successfully completed. Functional prototypes were produced that impressed with their rapid dissolution and homogeneous texture. On this basis, BioNxt is already preparing the patent application. This will ensure that the intellectual property remains protected.

Shortly thereafter, BioNxt strengthened its communications by hiring two investor relations experts. This measure signaled that the Company intends to communicate the expected operational progress to the markets in an appropriate manner. In addition, Terry Lynch will remain with the Company as a capital markets advisor.

The highlight of the month came on September 29 with a comprehensive update on the flagship project BNT23001, the cladribine sublingual thin-film for multiple sclerosis. The announcement was full of tangible operational milestones. The successful transfer of the manufacturing processes to its European contract development and manufacturing organization had been completed, and the active ingredient had been ordered and was on its way. Specifically, the Company is planning a bioavailability study in large animals for October 2025. This represents the final preclinical step before the first human application in the first quarter of 2026. Here, the operational chain closed seamlessly from laboratory concept to scalable production to the final preclinical test.

But BioNxt had another surprise in store. On October 2, the Company announced an update for a previously lesser-known technology platform: a targeted delivery platform for chemotherapeutic agents. That sounds technical, but the implications are revolutionary. The system uses a novel dual mechanism of action in which chemotherapeutic agents are not only explicitly released at the tumor, but "stray" drug molecules outside the tumor are neutralized. In vitro models showed up to a tenfold increase in therapeutic effect while protecting healthy cells.

The research team has already begun creating a molecular database and has identified a first priority candidate. The Company announced that it will sign a final agreement on this platform in the coming weeks, indicating an imminent partnership or financing deal.

The big picture: Why this string of successes matters

These announcements are not isolated press releases, but rather the pieces of a coherent strategy.

Every successful technology transfer and every successful prototype not only strengthens the respective project but also the underlying platform. The same sublingual thin film technology that is being perfected for cladribine in MS is being used for semaglutide in obesity. The newly unveiled chemotherapy platform once again demonstrates the Company's ability to address fundamental issues in drug delivery.

CEO Hugh Rogers summed up the significance of the advances in the cladribine program: "The progress we are reporting today reinforces our belief that this program is a key pillar in BioNxt's commercialization pipeline."

The potential leverage: From the lab to billion-dollar markets

Operational rigor opens the door to huge markets. The market for MS therapies is estimated at over USD 21 billion per year. Merck KGaA's cladribine tablet (Mavenclad®) is well established here. The BioNxt approach could offer decisive advantages. A sublingual thin-film that dissolves under the tongue bypasses swallowing difficulties and could have a more reliable effect.

The leverage is even greater in the obesity market. Sales of GLP-1 drugs such as semaglutide amounted to over USD 29 billion in 2024. An effective oral alternative in the form of a dissolvable film, without needles, could revolutionize treatment adherence. Analysts forecast growth in this segment to around USD 150 billion by 2030.

The newly introduced chemotherapy platform also positions BioNxt in the global oncology market, which Data Bridge forecasts will grow from USD 47 billion (2022) to USD 98 billion by 2030. The new dosage form, which goes directly into the bloodstream, also opens up the possibility for the Company to breathe new life into older chemotherapy drugs that have been abandoned due to excessive side effects.

The proprietary platform technologies offer the opportunity for strategic collaboration with large pharmaceutical companies. Every operational advance increases the technological maturity and thus the potential value of such a partnership. However, success could also position the Company as a takeover target.

Analysts at Black Research currently see a price target of EUR 2.50. The stock is currently trading at just CAD 0.83.

The sequence of announcements from September to early October 2025 has shown that BioNxt Solutions is more than just a collection of interesting ideas. The Company demonstrates a remarkable ability to advance multiple technology platforms in parallel and according to plan. From the procurement of active ingredients to proof-of-concept studies to scalable production processes and the announcement of a groundbreaking cancer therapy, the value story is gaining substance every month. For investors who believe in the disruptive power of novel drug delivery, BioNxt offers a multi-layered opportunity to participate in several billion-dollar markets simultaneously. The foundation for commercial success is currently being laid piece by piece.